S
Spero Therapeutics, Inc. (SPRO)
NMS – Real Time Price. Currency in USD
2.54
-0.01 (-0.39%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.54
-0.01 (-0.39%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 7.59 | 6.05 | 10 | |
| Quick ratio | 7.59 | 5.63 | 10 | |
| Debt to Equity | 0.05 | 0.30 | 9.0 | |
| Debt to Assets | 0.04 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 10 | |
| Weighted average score | 9.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 49M | 97M | 27M | 60M | 60M |
| Gross Profit | 47M | 96M | 27M | N/A | N/A |
| Operating Income | -35M | 20M | -93M | -24K | -24K |
| Net Income | -46M | 23M | -69M | 9M | 9M |
| EBITDA | -34M | 20M | -93M | -24K | -24K |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 28 | 5.5 |
| Next quarter | N/A | -466.67 | 1.0 |
| Current year | -98.8 | 346.67 | 5.5 |
| Next year | 300 | -201.49 | 5.5 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 1201.12 | 526.98 | 507.69 | -147.92 | 7.8 |
| Y/Y | 323.88 | 250.9 | 239.47 | 64.31 | 10 |
| 3y average | 48.36 | -46.33 | -49.51 | -83.88 | 3.3 |
| 5y average | 543.48 | -21.06 | -14.69 | -83.88 | 3.3 |
| Weighted average score | 6.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $40.3M significantly exceed its total debt $2.9M, ensuring strong financial flexibility
Total current assets $67.3M exceed Total current liabilities $8.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
The company has no interest-bearing debt, showcasing excellent financial strength
Negative free cash flow -$8.4M limits the company's ability to reinvest or pay down debt